Announcements Trials

Browse Landscape

Phase

Phase NA 1 Phase 2 1 Phase 1/2 1

Status

Enrolling by invitation 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 2760 Carcinoma, Non-Small-Cell Lung 2260 Prostatic Neoplasms 1425 Colorectal Neoplasms 1290 Neoplasms 1258 Multiple Myeloma 1084 Lung Neoplasms 1048 Neoplasm Metastasis 994 Leukemia, Myeloid, Acute 984 Lymphoma 900 Melanoma 862 Pancreatic Neoplasms 818 Ovarian Neoplasms 805 Carcinoma, Hepatocellular 782 Stomach Neoplasms 753 Recurrence 750 Leukemia 733 Lymphoma, Non-Hodgkin 684 Leukemia, Lymphocytic, Chronic, B-Cell 665 Lymphoma, Large B-Cell, Diffuse 616 Squamous Cell Carcinoma of Head and Neck 615 Precursor Cell Lymphoblastic Leukemia-Lymphoma 605 Head and Neck Neoplasms 596 Brain Neoplasms 592 Carcinoma, Renal Cell 586 Glioblastoma 572 Rectal Neoplasms 563 Myelodysplastic Syndromes 522 Sarcoma 521 Lymphoma, Follicular 516

Interventions

130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × TNBC × Clear all

NCT07376629 2026-01-29

A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC

Huabo Biopharm Co., Ltd.

Phase 2 Enrolling by invitation

TNBC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡